Digital China and INSEAD Jointly Release First AI Case
In his speech, Guo Wei pointed out that the interaction of Business Model, Technology Architecture, and Management Approach forms a growth flywheel that drives enterprise evolution—at the core of which lies business processes. Therefore, deeply integrating AI into the reengineering of business processes will be key to the commercialization of AI. To achieve process reengineering and meet the management goals in the AI era—full-scope awareness, rapid decision-making, and continuous iteration—enterprises must first rebuild their infrastructure. This means aligning business processes with a new data cloud integrated architecture, to fully harness the value of data assets.
When discussing AI's impact on organizational transformation, Guo Wei said, "From an enterprise perspective, every wave of technological change brings enormous opportunities, and also significant challenges. The biggest challenge lies in building the right mindset. There's a great deal of enthusiasm for AI in the public discourse, but its actual application in enterprise settings is still at an early stage. This gap often leads to fatigue and anxiety. We firmly believe that AI and digitalization will drive profound changes, but such transformation won't happen overnight—it requires a gradual, step-by-step process."
Now included in the INSEAD Case Library and soon to become part of its MBA curriculum, the case study "Shaping the Future: Digital China's Journey from Digitalization to an AI-Embedded Organization" provides global learners with insights into AI-led transformation and reflects China's growing influence on enterprise AI innovation.
This case study presents Digital China's journey in digital transformation and its latest AI initiatives under the strategic framework of "AI-Powered Data Cloud Integration." Reflecting global digital and AI trends, it offers valuable insights for companies pursuing similar transformations. Following earlier inclusion in the case libraries of London Business School and Harvard Business School in 2024, this latest inclusion by INSEAD further showcases Digital China's leadership and China's growing influence in shaping global AI innovation.
Professor Chen Guoli remarked: "This case firmly validates Digital China's AI transformation methodology and enriches global academic research by contributing to the theoretical framework of digital transformation and AI application—bridging Chinese practice with the global academic community."
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/digital-china-and-insead-jointly-release-first-ai-case-302469355.html
SOURCE Digital China
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Cerence Inc. (CRNC) Might Be A Hidden Gem, Says Jim Cramer
We recently published . Cerence Inc. (NASDAQ:CRNC) is one of the stocks Jim Cramer recently discussed. Cerence Inc. (NASDAQ:CRNC) is a software company that caters to the needs of the transportation industry. Its shares have gained 60% year-to-date and gained an unbelievable 45% in August. Cerence Inc. (NASDAQ:CRNC) is benefiting from the AI wave through having landed major deals, such as a partnership with Mercedes-Benz. Cramer discussed the firm in the context of it being an outlier that could be interesting in the AI era: 'I'm doing a piece about Cerence tonight. People are going to want to find out what I'm saying there. There's a lot of technology away from these big companies that is better than the big companies.' Copyright: audioundwerbung / 123RF Stock Photo Here are Cramer's previous thoughts about Cerence Inc. (NASDAQ:CRNC): 'I like Cerence, and I also happen to like Brian Krzanich, the CEO. I am partial. They make money. I think you've got a winner. I was actually trying to figure out whether I could justify doing a piece on it because it's not that expensive. Cerence is a winner, and Brian's always welcome on the show, as we know.' While we acknowledge the potential of CRNC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Jetstar passenger's warning after 'confusing' Bali flight ordeal: 'Don't wait'
A Jetstar passenger has hit out at the budget airline after an apparent airline tactic of overbooking flights left her potentially facing a long wait for another plane. Young Aussie Sky Kennedy told Yahoo News she was getting ready to fly home after a two-week solo adventure around Bali when, at the check-in desk, she was told she may be refused boarding because she hadn't pre-booked a seat. "When I got to the desk, the lady mentioned that the plane was full and because I hadn't selected a seat, that I didn't actually have one secured on that flight," Sky recalled for Yahoo News. Sky said she was "confused" because she'd booked the flight months ago. "She explained that even though I bought the ticket, because I hadn't selected a seat, it wasn't guaranteed," she said. Seat selection on Jetstar flights – do you have to buy a seat? Basic seat selection on Jetstar flights costs around $8, while seats closer to the front and on exit rows can go for up to $32. For Sky, she usually doesn't select a seat because she's "happy to sit anywhere". "If I had known that choosing a seat meant my booking wasn't secured, I would have, of course, selected one," she said. "But when you book online, it doesn't say that and even gives you the option to skip seat selection. If it's essential to secure your ticket, in my opinion, it should be included in the price or mentioned at the time of booking." Yahoo contacted Jetstar to find out if what Sky was told in Bali is airline policy. Jetstar advised that customers aren't required to pre-purchase seats to guarantee travel. If a flight is overbooked, Jetstar can choose passengers to change to another flight. It will provide affected passengers with compensation, reimbursement and assistance to secure another flight, the airline's policy says. Sky said once on board, the people next to her said they had booked the seat for their friend who was suddenly hospitalised with Covid. 😱 Jetstar passenger's incredible spot from window of Bali flight ✈️ Calls for Jetstar to change policy to resolve 'ridiculous' problem 🧳 Jetstar carry-on policy questioned after 'ridiculous' passenger request Sky, who shared her story online, said she learned that airlines are known to overbook flights, expecting that some passengers won't show up. On its website, Jetstar says flights may be overbooked "on rare occasions". Following her experience, Sky has warned Aussies to leave nothing to chance and simply pay the $8 fee. "Pay the extra however much it is for your seat and check in as soon as you can, don't wait until you get to the airport," she warned. Yahoo understands that Jetstar has apologised to Sky for the distress the incident caused her. On occasion, passengers aren't able to be accommodated due to a change in aircraft, weight restrictions, or, in rare circumstances, when a flight is overbooked. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.
